TX-RIVERSAND
7.10.2020 08:02:14 CEST | Business Wire | Press release
Digital Consulting firm ADROSONIC, today announced a strategic partnership with Riversand, a US-based multidomain Master Data Management (MDM) and Product Information Management (PIM) solution provider, to develop and deliver cloud-native MDM and PIM solutions with rapid deployment to Insurance markets, specifically in the UK and the USA.
Recognised as the only Visionary by Gartner in its Magic Quadrant for Master Data Management, Riversand has disrupted the traditional PIM and MDM markets. ADROSONIC will leverage its Insurance domain knowledge and success in the UK Insurance market with Riversand’s technology to create strategic and competitively advantageous solutions for its clients. Beyond Insurance, ADROSONIC’s depth includes other domains such as Manufacturing.
“ADROSONIC's strong domain knowledge within Insurance, Manufacturing and Social Welfare organisations is unparalleled in Europe and the US,” said Jasleen Ahluwalia, vice president of Business Development at Riversand. “Their extensive experience in delivering multiple complex data projects, combined with their expertise in Quality Assurance and Automation and fast implementation, will benefit customers and help them realize better competitive value.”
“Riversand’s intuitive, 100 percent cloud-native MDM and PIM solution caters to both B2B and B2C markets. When coupled with ADROSONIC’s domain knowledge and expertise in handling complex data projects and comprehensive delivery methodology, this promises cost efficiency and quicker time-to-value, thus lowering the total cost of ownership for the business,” said Mr. Mayank, CEO and MD at ADROSONIC. “Organisations going through a digital transformation journey are looking for MDM solutions that can be integrated with their cloud-first strategy and our combined efforts fit perfectly with their needs.”
About Riversand
Riversand’s cloud-native master data management solutions are designed to support customers’ digital transformation journeys through improved business agility, faster adoption and improved collaboration across the enterprise. Driving data to experiences, Riversand has a vision of helping companies know their customers better, move products faster, automate processes, mitigate risk and run their businesses smarter. Visit https://Riversand.com for more information and follow us @RiversandMDM on Twitter and Riversand on LinkedIn.
About ADROSONIC
ADROSONIC is an innovative, business-focused Digital consulting firm empowering organisations with a complete framework of IT Solutions and Services. A trusted partner for both service and product-based companies, ADROSONIC has a global presence with offices in India, UK and the USA. Possessing competencies in the fields of Robotic Process Automation, Data Analytics, CRM services, Application Services, Digital Quality Assurance and Software Testing, ADROSONIC strives to pave the Digital Roadmap for emerging and traditional business organisations. Reach out to us at www.adrosonic.com and follow us on @adrosonic on Twitter and ADROSONIC on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom